Paratek Advances Timing of Top-Line Data for Phase 3 Community Acquired Bacterial Pneumonia Study to the Second Quarter of 2017
December 13, 2016 07:00 ET
|
Paratek Pharmaceuticals
BOSTON, Dec. 13, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies...
Paratek Pharmaceuticals, Inc. Reports Third Quarter 2016 Financial Results and Provides Clinical Updates
November 02, 2016 07:30 ET
|
Paratek Pharmaceuticals
Successfully demonstrated proof-of-principle in a Phase 1b study of oral and IV omadacycline in patients with urinary tract infections (UTI)Completed all clinical phase 1 studies and...
Paratek Pharmaceuticals, Inc. to Host R&D Day on November 17, 2016
October 26, 2016 08:00 ET
|
Paratek Pharmaceuticals
Webcast on Thursday, November 17, 1:00 p.m. at www.paratekpharma.com BOSTON, Oct. 26, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company...
Paratek Pharmaceuticals to Report Third Quarter 2016 Financial Results and Provide Update on Clinical Progress on November 2, 2016
October 24, 2016 08:00 ET
|
Paratek Pharmaceuticals
BOSTON, Oct. 24, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based...
Paratek, U.S. Department of Defense Enter Research Agreement to Study Omadacycline Against Biodefense Pathogens
October 11, 2016 08:00 ET
|
Paratek Pharmaceuticals
BOSTON, Oct. 11, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) announced today it has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Army...
Paratek to Ring Nasdaq Closing Bell Recognizing 20th Anniversary
October 04, 2016 08:00 ET
|
Paratek Pharmaceuticals
BOSTON, Oct. 04, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) will today ring the closing bell at Nasdaq to mark the company’s 20th anniversary of working to develop new...
Paratek Pharmaceuticals, Inc. To Present at Two Upcoming Investor Conferences
September 01, 2016 08:00 ET
|
Paratek Pharmaceuticals
BOSTON, Sept. 01, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) today announced that the company will participate in two upcoming investor conferences. Paratek is a...
Paratek Initiates Phase 3 Study of Oral-only Omadacycline in ABSSSI
August 15, 2016 08:00 ET
|
Paratek Pharmaceuticals
BOSTON, Aug. 15, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) announced today the dosing of the first patient in its second pivotal Phase 3 study of omadacycline in...
Paratek Pharmaceuticals, Inc. Reports Second Quarter 2016 Financial and Operating Results
August 04, 2016 07:00 ET
|
Paratek Pharmaceuticals
Reported positive Phase 3 study results with omadacycline in acute bacterial skin and skin structure infections Accelerated timing to report top-line data of the omadacycline Phase 1b urinary...
Paratek Pharmaceuticals to Report Second Quarter 2016 Financial Results on August 4, 2016
July 22, 2016 10:57 ET
|
Paratek Pharmaceuticals
BOSTON, July 22, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon...